Georgia Made Medical Manufacturing Act Signed Into Law

On Tuesday, May 4th, Governor Kemp signed Senate Bill 6 into law. SB 6 contains language for the Georgia Made Medical Manufacturing Act, which allows for an additional $1250 tax credit for all new jobs engaged with pharmaceutical and medical supply/device manufacturing. Language for the GMMMA was previously included on several pieces of legislation but received final passage on the last day of session on a Conference Committee Report to SB 6. The law will go into effect on July 1, 2021.

This legislation signals the value that Gov. Kemp and the General Assembly place on the important work of the life sciences industry. We thank them for their support and look forward to working with them to expand our industry and its economic impact here in Georgia.

Click here for full text of Senate Bill 6

Georgia Bio with Gov. Brian Kemp at the bill signing ceremony for Senate Bill 6.
From L to R: Ashley Haltom, Maria Thacker-Goethe, Gov. Brian Kemp, Shay Foley, Karla Kiriako

The post Georgia Made Medical Manufacturing Act Signed Into Law appeared first on Georgia Bio.

< Older Post

Newer Post >

September GBG Report Now Available – Federal Funding Insights for Georgia Life Sciences Members

September 11, 2025

Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.